Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Patch Clear all
Recruiting Phase 1 Interventional

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

NCT04701645
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage IV, Fallopian Tube Cancer Stage III
Interventions
Microdevice
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

NCT02886702
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tazarotene Cream 0.05%, TAZORAC® (tazarotene) Cream 0.05%, Placebo
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 25, 2026, 5:14 PM EDT
Active, not recruiting Early Phase 1 Interventional

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

NCT04541108
View directory record Official record
Conditions
Solid Tumor
Interventions
Rilvegostomig, Volrustomig, Sabestomig, Pembrolizumab, AZD9592, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
9
States / cities
Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

NCT06238817
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Little Rock, Arkansas • Fountain Valley, California • Fremont, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 5:14 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

NCT00871208
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Altabax (R), Vehicle and Locoid lipocream (R)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
9 Months to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects

NCT03472547
View directory record Official record
Conditions
Healthy
Interventions
diacerein 1% ointment
Drug
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

NCT01986920
View directory record Official record
Conditions
Seborrheic Keratosis (SK)
Interventions
A-101 25%, A-101 32.5%, A-101 40%, A-101 Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745638
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

NCT04883593
View directory record Official record
Conditions
Tinea Pedis
Interventions
TA103, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT03142451
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
54
States / cities
Tucson, Arizona • Fremont, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

NCT03837743
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DUR-928 Topical Solution, Vehicle Topical Solution
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ibuprofen 5% Topical Gel CIPT

NCT01771822
View directory record Official record
Conditions
Pain
Interventions
Ibuprofen 5% topical gel, Topical gel vehicle, Sodium lauryl sulfate 0.2%, Sodium chloride solution 0.9% (saline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Carlstadt, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745651
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face

NCT04085367
View directory record Official record
Conditions
Actinic Keratoses
Interventions
MAL 16.8% cream, MAL Vehicle Cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
59
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Encinitas, California + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT04608500
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
46
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

NCT06369675
View directory record Official record
Conditions
Erythema
Interventions
MOB015B, 0.2% SLS, 0.9% Saline, MOB015B vehicle
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Study of SOR007 Ointment for Actinic Keratosis

NCT03083470
View directory record Official record
Conditions
Actinic Keratosis
Interventions
SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment, SOR007 Ointment Vehicle
Drug · Other
Lead sponsor
DFB Soria, LLC
Industry
Eligibility
45 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Repeat Insult Patch Test of Wound Dressings

NCT01368146
View directory record Official record
Conditions
Skin Sensitization
Interventions
IV Clear™, Tegaderm CHG™, Silicone Vehicle Control Dressing
Device
Lead sponsor
Covalon Technologies Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phototoxicity Potential of NatrOVA Creme Rinse - 1%

NCT00591331
View directory record Official record
Conditions
Head Lice
Interventions
Spinosad (the active ingredient in NatrOVA), placebo
Drug
Lead sponsor
ParaPRO LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

NCT05799157
View directory record Official record
Conditions
Verruca Vulgaris, Warts, Common Wart
Interventions
VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
9 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

NCT01119651
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene (Patch application in Challenge Phase)
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol

NCT05260359
View directory record Official record
Conditions
Sunburn
Interventions
6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation, 6% Bemotrizinol (BEMT) dispersion in petrolatum, Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT, Petrolatum vehicle, 0.9% Saline, Sodium Lauryl Sulfate 0.1% (SLS), Undosed patch
Drug · Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 25, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis

NCT04243486
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
UHE-105, Vehicle
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
San Diego, California • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 25, 2026, 5:14 PM EDT